MedTrace Logo

Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant

NCT01426828 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-12-04

Study results available
· View outcomes & findings →

Summary

This study will enroll myeloma subjects undergoing autotransplantation. The primary objective of this study is to evaluate whether infusions of Id-KLH primed CD3/CD28 activated autologous lymphocytes mediate a more intense Id-specific immunity than non Id-KLH primed CD3/CD28 activated autologous lymphocytes. There will be 2 arms in the study, one receiving a DLI with non Id-KLH vaccine and one receiving aDLI with Id-KLH vaccine.

Conditions

Interventions

BIOLOGICAL

CD3/CD28

CD3/CD28 activated autologous lymphocytes intravenously

Sponsors & Collaborators

Principal Investigators

  • Ed Stadtmauer, MD · Abramson Cancer Center at Penn Medicine

  • Muzaffar H. Qazilbash, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2016-06-30
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01426828 on ClinicalTrials.gov